Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04114903 · ClinicalTrials.gov registry record
Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity
A clinical trial, sponsored by University of Colorado, Boulder.
- Completed
- Registry status
- 255
- Enrollment target
NCT04114903 is a clinical trial that has completed, run by University of Colorado, Boulder. The registered enrollment target is 255 participants.
The verdict
NCT04114903 has completed, sponsored by University of Colorado, Boulder.
- COMPLETED
- Registry status
- 255 participants
- Enrollment target
Study Summary
This study tests the effects of cannabinoid levels in blood on inflammation and insulin sensitivity both acutely and chronically in individuals across the weight spectrum. To that end, the study employs two observational designs: 1) A study of acute effects with intermittent cannabis users and 2) A study in which current cannabis users will select one of three cannabis strains for four weeks and are compared to a matched control group who do not use cannabis to study chronic effects. Blood levels of THC and CBD, inflammatory biomarkers, and insulin resistance will be measured in both studies.
Interventions
- OTHER Study A: Single use of cannabis flower product
- OTHER Study B: Ad libitum cannabis use for four weeks or no cannabis use
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2019-11-08 |
| Est. Completion | 2024-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04114903
The ClinicalTrials.gov registry entry for NCT04114903 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Boulder, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Study A: Single use of cannabis flower product is the first listed.
NCT04114903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04114903 about?
NCT04114903 is a clinical study titled "Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity". This study tests the effects of cannabinoid levels in blood on inflammation and insulin sensitivity both acutely and chronically in individuals across the weight spectrum. To that end, the study employs two observational designs: 1) A study of acute effects with intermittent cannabis users and 2) A ...
What is the current status of trial NCT04114903?
This trial is currently completed. The enrollment target is 255 participants. The study started on 2019-11-08. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT04114903?
The interventions under investigation include: Study A: Single use of cannabis flower product (OTHER), Study B: Ad libitum cannabis use for four weeks or no cannabis use (OTHER).
Who is sponsoring clinical trial NCT04114903?
This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.